Current drug therapy for multiple myeloma

Drugs

Volumn 57, Issue 4, 1999, Pages 485-506

  Huang, Yi Wu ^a   Hamilton, Audrey ^a   Arnuk, Omar J ^a   Chaftari, Patrick ^a   Chemaly, Roy ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DEXNIGULDIPINE; DOXORUBICIN; ELACRIDAR; ERYTHROPOIETIN; ETOPOSIDE; GLYCOPROTEIN P; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AMYLOIDOSIS; ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE LESION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA;

EID: 0032917058     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957040-00004     Document Type: Review

References (201)

1. 1. Young JL, Percy CL, Asire AJ. Surveillance epidemiology end results: incidence and mortality data. 1973-1977. NCI monograph 57. Bethesda (MD): Department of Health and Human Services, NIH, 1981: ZS 81
2. 2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975:50: 29-40
3. 3. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1998; 48: 6-48
4. 4. Kyle RA. Benign monoclonal gammopathy after 25-35 years of follow up. Mayo Clin Proc 1993; 68: 26-36
5. 5. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21
6. 6. Sahota SS, Leo R, Hamblin TJ, et al. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 1997; 90: 1334-5
7. 7. Bataille R. New insights in the clinical biology of multiple myeloma. Semin Hematol 1997; 34 Suppl. 1: 23-8
8. 8. Huang YW, Vitetta ES. Immunotherapy of multiple myeloma. Stem Cells 1995; 13: 123-34
9. 9. Hardin J, MacLeod S. Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-70
10. 10. Hata H, Matsuzaki H, Takeya M, et al. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995; 86: 1939-45
11. 11. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-21
12. 12. Uchiyama H, Barut BA, Mohrhacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712-20
13. 13. Rettig MB, Ma HJ, Vescio RA, et al. Kaposis sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276: 1851-4
14. 14. Rettig M, Vescio R, Ma H, et al. Detection of Kaposi's sarcomaassociated herpesvirus in the dendritic cells of Waldenstroms macroglobulinemia and primary amyloidosis patients [abstract]. Blood 1997; 90 Suppl. 1: 86a
15. 15. Gramatzki M, Burger R, Neipel F, et al. Human herpesvirus type 8 (HHV-8) interleukin-6 homologue is functionally active on human myeloma cells (abstract]. Blood 1997; 90 Suppl. 1:87a
16. 16. Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 1997; 90: 4278-82
17. 17. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffman AV, Bran MG, Hirsh J, editors. Recent advances in hematology. Edinburgh: Churchill Livingstone, 1977: 243-61
18. 18. Kyle RA, Greipp PR. Smouldering multiple myeloma. N Engl J Med 1980; 302: 1347-9
19. 19. Alexanian R. Localized and indolent myeloma. Blood 1980; 56: 521-5
20. 20. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-54
21. 21. Cavo M, Baccarini M, Galieni P, et al. Renal failure in multiple myeloma: a study of the presenting findings, response to treatment and prognosis in 26 patients. Nouv Rev Fr Hematol 1986; 28: 147-52
22. 22. Greipp PR, Katzmann JA, O Fallon WN, et al. Value of beta 2 microglobulin level and cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-23
23. 23. Greipp RR, Lust JA, O Fallon WM, et al. Plasma cell labeling index and B2-microglobulin predict survival independent of thymidine kinase and c-reactive protein in multiple myeloma. Blood 1993; 81: 3382-7
24. 24. Barlogie B, Smallwood L, Smith T, et al. High serum levels of lactate dehydrogenase identify a high grade lymphoma like myeloma. Ann Intern Med 1989; 110: 521-5
25. 25. Vesole DH, Tricot G, Jagannath S, et al. Autotransplantations in multiple myeloma: what have we learned? Blood 1996; 88: 838-47
26. 26. Greipp PR, Raymond NM, Kyle RA, et al. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305-10
27. 27. Dewald GW, Kyle RA, Hicks GA, et al. The clinical significance of cytogenetic studies on 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood 1985; 66: 380-90
28. 28. Durie BGM, Grogan TM. CALLA positive myeloma: an aggressive subtype with poor survival. Blood 1985; 66: 224-232
29. 29. Omede P, Boccadoro M, Gallone G, et al. Multiple myeloma: increased circulating lymphocytes carrying plasma cell associated antigens as an indicator of poor survival. Blood 1990; 76: 1375-9
30. 30. Oimino G, Avvisati G, Amadori S, etal. High serum 1L-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol 1990; 75: 373-7
31. 31. Ludwig H, Nachbaur DM, Fritz E, et al. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 77: 2794-5
32. 32. Greipp PR, Gaillard JP, Kalish LA, et al. Independent prognostic value for serum soluble interleukin-6 receptor (s1L-6R) in Eastern Cooperative Oncology group (ECOG) myeloma trial E-9487 [abstract]. Proc Am Soc Clin Oncol 1993; 12: 404
33. 33. Bataille R, Barlogie B, Lu ZY, et al. Biologie effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685-91
34. 34. Feinman R, Sawyer J, Hardin J, et al. Cytogenetics and molecular genetics in multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 1-25
35. 35. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-6
36. 36. Wch HJ, Gutensohn K, Selbach J, et al. Karyotype in multiple myeloma and plasma cell leukemia. Eur J Cancer 1993; 29A: 1269-73
37. 37. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659-66
38. 38. Alexanian R, Haut A, Khan A. The treatment of multiple myeloma. JAMA 1969; 208: 1680-5
39. 39. Boccadoro M and Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 111-31
40. 40. Oken MM. Multiple myeloma. Med Clin North Am 1984; 68: 757-87
41. 41. Bergsagel DE. Use a gentle approach for refractory myeloma patients. J Clin Oncol 1988; 6: 757-8
42. 42. Bosanquet AG, Gilby ED. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 1982; 18: 355-62
43. 43. Ehrsson H, Eksborg S, Osteborg A, et al. Oral melphalan pharmacokinetics: relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 1989; 6: 151-4
44. 44. Fernberg JO, Johansson BO, Lewensohn R, et al. Oral dose of melphalan and response to treatment. Eur J Cancer 1990; 26: 393-6
45. 45. Raaijmakers HGP, Izquierdo MHI, Lokhorst HM, et al. Lung-resistance-related protein expression in a negative predictive factor for response to conventional low but not intensified dose alkylating chemotherapy in multiple myeloma. Blood 1997; 91: 1029-36
46. 46. Oken MM. Standard treatment of multiple myeloma. Mayo Clin Proc 1994; 69: 781-6
47. 47. Bergsagel DE, Bailey AJ, Langley GR, et al. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-8
48. 48. Zulian G. Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management. Semin Hematol 1997; 34 Suppl. I: 29-39
49. 49. Oken MM, Harrington DP, Abramson N, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79: 1561-7
50. 50. Salmon SE, Haut A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1983; 1:453-61
51. 51. Oken MM. Multiple myeloma: prognosis and standard treatment. Cancer Invest 1997; 15: 57-64
52. 52 MacLennan IC, Chapman C, Dunn J, et al. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukemia in Adults. Lancet 1992; 339: 200-5
53. 53. Ballesler OF, Moscinski LL, Fields KK, et al. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Br J Haematol 1997; 96: 746-8
54. 54. Dimopoulos MA, Delasalle KB, Champlin R, et al. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistam multiple myeloma. Br J Haematol 1993; 83: 240-4
55. 55. Barlogie B, Velasquez WS, Alexanian R, et al. Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin and dexamethasone-refractory myeloma. J Clin Oncol 1989; 7: 1514-7
56. 56. Salmon SE, Crowley JJ, Grogan TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2405-14
57. 57. Alexanian R, Dimopolous MA, Delasalle K, et al. Primary dexamethasone treatmenl of multiple myeloma. Blood 1992; 80: 887-90
58. 58. Alexanian R, Dimopolous M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-9
59. 59. Case Jr DC, Lee DJ III, Clarksoc BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU: M-2 protocol. Am J Med 1977; 63: 897-903
60. 60. Durie BG, Dixon DO, Carter S, et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1986; 4: 1227-37
61. 61. Alexanian R, Barlogie B, Tucker S. VAD based regimens as primary treatment of multiple myeloma. Am J Hematol 1990; 33: 86-9
62. 62. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-42
63. 63. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-64
64. 64. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430-4
65. 65. Joshua DE, Penny R, Baldwin K, et al. The study of combination therapy plus or minus roferon A in multiple myeloma [abstract]. Blood 1994; 84 Suppl. I: 179a
66. 66. Jagannath S, Tricot G, Desikan KR, et al. Double autotransplants (DAT) for 542 patients with multiple myeloma (MM) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 14a
67. 67. Kyle RA. Newer approaches to the therapy of multiple myeloma. Blood 1990, 76: 1678-9
68. 68. Barlogie B, Smith E, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-6
69. 69. Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11
70. 70. Monconduit M, Le Loet X, Bernard JF, et al. Combination chemotherapy with VAD for refractory or relapsing multiple myeloma. Br J Haematol 1986; 63: 599-601
71. 71. Sheehan T, Judge M, Parker AC. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders. Scand J Haematol 1986; 37: 425-8
72. 72. Kovacsovics TJ, Delaly A. Intensive treatment strategies in multiple myeloma. Semin Hematol 1997; 34 Suppl. I: 49-60
73. 73. Dimopoulos MA, Hester J, Huh Y, et al. Intensive chemotherapy with blood progenitor transplantation for primary resistant myeloma. Br J Haematol 1994; 87: 730-4
74. 74. Tricot G, Jagannath S, Vesole DH, et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7-11
75. 75. Attal M, Harousseau JE. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997; II: 133-45
76. 76. Goldschmidt H, Hegenbart U, Wallmeier M, et al. Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy. Recent Results Cancer Res 1998; 144: 27-35
77. 77. Barlogie B, Alexanian R, Smallwood E, et al. Prognostic factors, with high dose melphalan for refractory myeloma. Blood 1988; 72:2015-9
78. 78. Cunningham D, Pas-Ares L, Gore ME, et al. High dose melphalan for multiple myeloma: long term follow-up data. J Clin Oncol 1994; 12: 764-8
79. 79. Harousseau JL, Milpied N, Laporte JP, et al. Double intensive therapy in high risk multiple myeloma. Blood 1992; 79: 2827-33
80. 80. Sonneveld P, Durie BG, Lokhorst C, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporine. The leukemia Group of the EORTC and the HOVON. Lancet 1992; 340: 255-9
81. 81. Moreau P, Fiere D, Bezwoda WR, et al. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 1997; 15:660-6
82. 82. Harousseau JL, Facon T, Maloisel F, et al. G-CSF instead of autologous stem cell transplantation after high dose melphalan as front line therapy in multiple myeloma [abstract]. Blood 1995;86 Suppl. I: 184a
83. 83. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-85
84. 84. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated myeloma. Blood 1992, 79: 1130-6
85. 85. Dimopoulos MH, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-8
86. 86. Schiller G, Nimers S, Vescio R, et al. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant 1994; 14: 131-6
87. 87. Anderson KC, Anderson J, Soiffer R, et al. Monoclonal anti-body-purged bone marrow transplantation therapy for multiple myeloma. Blood 1993; 82: 2568-76
88. 88. Reece DE, Barnett MJ, Connors JM. Treatment of multiple myeloma with intensive chemotherapy followed by autologous bone marrow transplantation using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993; 11: 139-46
89. 89. Fermand JP, Revaud P, Chevret SC, et al. Early versus late high dose therapy and autologous peripheral blood stem cell transplanlation in multiple myeloma [abstract]. Blood 1996; 88: 685a
90. 90. Alexanian R, Dimopoulos M, Smith T, et al. Early myeloahlastive therapy for multiple myeloma. Blood 1994; 84: 4278-82
91. 91. Attai M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelomae. N Engl J Med 1996; 335: 91-7
92. 92. Rebihou JM, Caillot D. Casasnovas RO, et al. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplant 1997; 20: 63-5
93. 93. Tricot U, Alberts DS, Johnson CS, et al. Safely of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947-52
94. 94. Mansi J, da Costa F, Viner C, et al. High-dose busulfan in patients with myeloma. J Clin Oncol 1992; 10: 1569-73
95. 95. Mehta J, Ayers D, Mattox S, et al. High-dose melphalan and autotransplantation in myeloma with renal impairment: a matched-pair comparison with patients without renal failure [abstract]. Blood 1997; 90 (Suppl. I, Pt 1): 419a
96. 96. Bensinger WI, Bucker CD, Gahrton G. Allogenic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 147-57
97. 97. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-8
98. 98. Verdonk LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases. Lancet 1996; 347: 800-1
99. 99. Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995; 32: 60-79
100. 100. Gahrton G, Tura S, Ljungman P, et al. Allogenic bone marrow transplantation in multiple myeloma. European Group for Blood and Marrow Transplantation. N Engl J Med 1991 ; 325: 1267-73
101. 101. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogenic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-22
102. 102. Durie BGM, Gale RP, Horowitz MM. Allogeneic and twin transplants for multiple myeloma: an IBMTR analysis [abstract]. Blood 1994; 84: 202a
103. 103. Marit G, Facon T, Jouet JP, et al. Allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moeile (SFGM) [abstract]. Blood 1997; 90: 226a
104. 104. Mehta J, Ayers D, Mattox S, et al. Allogeneic bone marrow transplantation in multiple myeloma: single-center experience of 97 patients [abstract]. Blood 1997; 90: 225a
105. 105. Schlossman RL, Anderson KC. Bone marrow transplantation of multiple myeloma. Cancer Invest 1997; 15: 65-75
106. 106. Majolino I, Tarella C, Seime R, et al. Allogeneic peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM) [abstract]. Blood 1997; 90: 390b
107. 107. Omede P, Tarella C, Palumbo A, et al. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 1997, 99: 685-91
108. 108. Henry JM, Sykes PJ, Brisco MJ, et al. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92: 614-9
109. 109. Raje N, Powles R, Horton C, et al. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 1997; 75: 1684-9
110. 110. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58
111. 111. Bjorkstrand B, Svensson H, Ljungman P, et al. 2522 autotransplants in multiple myeloma: a registry study from the European group for blood and marrow transplantation (EBMT) [abstract]. Blood 1997; 90 Suppl. 1: 419a
112. 112. Attal M, Harousseau JL, Stoppa AM, et al. High-dose therapy in multiple myeloma: an updated analysis of the IFM 90 protocol [abstract]. Blood 1997; 90 Suppl. I: 418a
113. 113. Barlogie B, Jagannath S, Epstein J, et al. Biology and therapy of multiple myeloma in 1996. Semin Hematol 1997; 34 Suppl. I: 67-72
114. 114. Jagannath S, Vesole D, Siegel D, et al. Final analysis of total therapy (TT) with tandem transplants (Tx) for 231 newly diagnosed patients (PTS) with multiple myeloma (MM) [abstract]. Blood 1997; 90 Suppl. I: 418a-9a
115. 115. Jagannath S, Tricot G, Barlogie B. Autotransplants in multiple myeloma: pushing the envelope. Hematol Oncol Clin North Am 1997; 11: 363-81
116. 116. Barlogie B, Jagannath S, Tricot G, et al. Advances in the treatment of multiple myeloma. Adv Intern Med 1998; 43: 279-320
117. 117. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-93
118. 118. Attal M, Payen C, Facon T, et al. Single versus double transplant in myeloma: a randomized trial of the 'Intergroupe Francais du Myelome' IFM [abstract]. Blood 1997; 90 Suppl. 1: 418a
119. 119. Schiller G, Stewart AK, Ballester O, et al. A phase III study evaluating CD34+ selection verus unselected autologous peripheral blood progenitor cell transplantation for patients with advanced multiple myeloma: engraftment results [abstract]. Blood 1997; 90 Suppl. I: 218a
120. 120. Avvisati G, Mandelli F. The role of interferon-a in the management of myelomatosis. Hematol Oncol Clin North Am 1992; 6: 395-405
121. 121. Bergsagel DE, Hans RH, Mesner HA. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 1986; 13 Suppl. 2: 21-34
122. 122. Welander CE, Mrogran TM, Homesley HD. Combined recombinant human interferon alpha and cytotoxic agents studied in the clongenic assay. Int J Cancer 1985; 35: 721-9
123. 123. Brow man GP, Bergsagel D, Sicheri D, et al. Randomized trial of Interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354-60
124. 124. Cooper MR, Dear K, McIntyre OR, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993; II: 155-60
125. 125. The Nordic Myeloma Study Group. Interferon-alfa 2h added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996; 124: 212-22
126. 126. Montuoro A, De Rosa L, De Blasio A, et al. Alpha-2a-interferon-melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990; 76: 365-8
127. 127. Osterborg A, Bjokholm M, Bjoreman M, et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428-34
128. 128. Joshua DE, Penny R, Matthews JP, et al. Australian Leukemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients wish myeloma. Br J Haematol 1997; 97: 38-45
129. 129. Abrahamson GM, Bird JM, Newland AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996; 94: 659-64
130. 130. Alexanian R, Barlogie B, Gutterman J. Alpha interferon combination therapy of resistant myeloma. Am J Clin Oncol 1991; 14: 188-92
131. 131. Grosbois B, Mary J-Y, Michaux J-L, et al. Interferon maintenance therapy in multiple myeloma patient achieving plateau phase after induction therapy: multicenter randomized trial [abstract]. Blood 1997; 90 Suppl. I: 356a
132. 132. Westin J, Rodjer S, Turesson I, et al. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89:561-8
133. 133. Cunningham D, Powles R, Malpas J, et al. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502
134. 134. Peest D, Deicher H, Coldway R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction and interferon-alpha for maintenance treatment in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A: 146-51
135. 135. Wisloff F. Hjirth M, Kaasa S, et al. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha interferon. The Nordic Myeloma Study Group. Br J Haematol 1996; 94: 324-32
136. 136. Meulopoulos L, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematological malignancies. Blood 1997; 90: 2127-47
137. 137. Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 349-61
138. 138. Jantunen E, Laakso M. Bisphosphonates in multiple myeloma: current status, future perspectives. Br J Haematol 1996; 93: 501-6
139. 139. Berenson JR, Lichtenstein A, Porter L, et al. for the Myeloma Aradia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93
140. 140. Lahtinen R, Laakso M, Palva I, et al. Randomized, placebo-controlled multicentre trial of clondronate in multiple myeloma. Finnish Leukemia Group. Lancet 1992; 340: 1049-52
141. 141. Niesvizky R, Warrell Jr RP. Pathophysiology and management of bone disease in multiple myeloma. Cancer Invest 1997; 15: 85-90
142. 142. McCloskey EV, Maclennan I, Grayson M, et al. Oral clondronate reduces skeletal morbidity in multiple myelomatosis [abstract]. Bone Miner 1994; 25 Suppl. 1: S80
143. 143. Riccardi A, Ucci G, Brugnatelli S, et al. A prospective, controlled, non-randomized study on prophylactic parental dichloromethylene bisphosphonate (clodronate) in multiple myeloma. Int J Oncol 1994; 5 Suppl. 4: 833-9
144. 144. Berenson JR. Bisphosphonates in multiple myeloma. Cancer 1997; 80 Suppl. 8: 1661-7
145. 145. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397-402
146. 146. Daragon A, Humez C, Michot C, et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur J Med 1993; 2: 449-42
147. 147. Rogers MJ, Watts DJ, Russell EGG. Overview of bisphosphonates. Cancer 1997; 80 Suppl. 8: 1652-60
148. 148. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cells: a novel antitumor activity. Br J Haematol 1997; 98: 665-72
149. 149. Savage AD, Belson DJ, Vescio RA, et al. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract]. Blood 1996; 88 Suppl. 1: 105a
150. 150. Paterson AD, Kanis JA, Cameron EC, et al. The use of dichloromethylene diphosphate for the management of hypercalcemia in multiple myeloma. Br J Haematol 1983; 54: 121-32
151. 151. Urwin GH, Yates AJP, Gray RES, et al. Treatment of hypercalcemia of malignancy with intravenous clodronate. Bone 1987; 8 Suppl. 1: S43-351
152. 152. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989; II: 1180-2
153. 153. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcemia with the bisphosphonate pamidronate. Ann Oncol 1994; 5: 359-6-3
154. 154. Thiebaud D, Jaeger P, Jacquet AF, et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988; 6: 762-8
155. 155. Burckhardt P. Ibandronate in oncology. Cancer 1997; 80 Suppl. 8: 1696-8
156. 156. Body JJ, Zoledronate: clinical research update. Cancer 1997; 80 Suppl. 8: 1699-701
157. 157. Warrell Jr RP, Lovett D, Dillmanian FA, et al. Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993; 11: 2443-50
158. 158. Warrell Jr RP, Isreal R, Frisone M, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemie: a randomized, double-blind comparison to calcitonin. Ann Intern Med 1988; 108: 669-74
159. 159. Warrell Jr RP, Murphy WK, Schulman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1992; 9: 1467-75
160. 160. Bertheault-Cvitkovic F, Armand J-P, Tubiana-Hulin M, et al. Randomized, double-blind comparison of pamidronate vs gallium nitrate for acute control of cancer-related hypercalcemia. Proceedings of the 9th EOTTC/NCI Symposium on New Drugs in Cancer Therapy. 1996: 140
161. 161. Warrell RP, Gallium nitrate for the treatment of bone metastases. Cancer 1997; 80 Suppl. 8: 1680-5
162. 162. Deftos LJ, Hypercalcemia: mechanisms, differential diagnosis and remedies. Postgrad Med 1996; 100: 119-26
163. 163. Dammacco F, Castoldi G, Roedjer S. A placebo-controlled study on the effect of epoetin alfa in patients with multiple myeloma [abstract]. Blood 1997; 90 (Suppl. 1, Pt 2): 358a
164. 164. Avvisati G, Petrucci MT, Mandelli F. The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Baillieres Clin Haematol 1995; 8: 815-29
165. 165. Musto P, Falcone A, DArena G, et al. Clinical results of recombinant erythropoietin in a transfusion-dependent patient with refractory myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997; 58: 314-9
166. 166. Silvestris F, Romito A, Fanelli P, et al. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995; 70: 313-8
167. 167. Berenson JR, Vescio RA, Schiller G. Multiple myeloma. In: Rakel RE, editor. Current therapy. Philadelphia (PA): Saunders Company, 1997: 424-9
168. 168. Barlogie B, Alexanian R and Jagannath S. Plasma cell dyscrasias. JAMA 1992; 268: 2946-51
169. 169. Comenzo R, Vosburgh H, Simms RW, et al. Dose-intensive melphalna with blood stem cell support for the treatment of AL amylodosis: one year follow in five patients. Blood 1996; 88: 2801-6
170. 170. Kyle RA, Gertz MA, Garton JP, et al. Primary systemic amyloidosis (AL): randomized trial of colchine vs melphalan and prednisone vs melphalan, prednisone and colchine. In: Kisilevsky R, Benson MD, Frangione B, et al, editors. Amyloid and amyloidosis. Park Ridge (NJ): Parthenon, 1993: 648-50
171. 171. Gianni L, Bellotti V, Gianni AM, et al. New drug therapy of amyloidoses: resorption of AL-type deposits with 4-iodo-4-deoxydoxorubiein. Blood 1995; 86: 855-61
172. 172. Xie Z., Zhao S, Konopleva M, et al. Melarsoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of Bel-2 apoptosis regulatory family [abstract]. Blood 1997; 90 Suppl. 1: 495a
173. 173. Sonneveld P, Lokhorst HM, Vossebeld P. Drug resistance in multiple myeloma. Semin Hematol 1997; 34 Suppl. 5: 34-9
174. 174. Dalton WS, Crowley JJ, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a South-west Oncology Group Study. Cancer 1995; 75: 815-20
175. 175. Sonneveld P, Marie JP, Huisman C, et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincrisline, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase 1 study. Leukemia 1996; 10: 1741-50
176. 176. Sonneveld P, Suciu S, Weijermans P, et al. Cyctosporin-A combined with VAD vs VAD in patients with refractory multiple myeloma: an EORTC/HOVON randomized phase II study [abstract]. Blood 1997; 90 Suppl. 1: 356a
177. 177. Sikic BI. Pharmacologie approaches lo reversing multidrug resistance. Semin Hematol 1997, 34 Suppl. 5: 40-7
178. 178. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363-82
179. 179. den Ouden D, van den Heuvel M, Schoesler M, et al. In vitro effect of GF 120918, a novel reversal agent of multi-drug resistance, on acute leukemia and multiple myeloma cells. Leukemia 1996; 10: 1930-6
180. 180. Yi Q. Osterborg A. Idiotypic-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Med Oncol 1996; 13: 1-7
181. 181. Reichardt VL, Okada CY, Stockerl-Goldstein KE, et al. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 1997, 3: 157-63
182. 182. Gobbi M, Tazzari PL, Cavo M, et al. Autologous bone marrow transplantation with immunotoxin purged marrow for multiple myeloma: long-term results in 14 patients with advanced disease [abstract]. Bone Marrow Transplant 1991; 7 Suppl. 1: 30a
183. 183. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-204
184. 184. Nishimoto N, Shima Y, Yoshizaki K, et al. Myeloma biology and therapy: present status and future development. Hematol Oncol Clin North Am 1997; 11: 159-72
185. 185. Peest D, Leo R, Bloche S, et al. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol 1995; 89: 328-37
186. 186. Kwak LW, Taub DD, Duffy PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immune marrow donor. Lancet 1995; 345: 1016-20
187. 187. Tarte K, Lu ZY, Fiol G, et al. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood 1997; 90: 3482-95
188. 188. Lim SH, Wen YJ, Ling M, et al. Idiotypic protein (ID)-pulsed adherent PBMC-derived dendritic cells (DC) prime immune system in multiple myeloma [abstract]. Blood 1997; 90 Suppl. 1: 358a
189. 189. Dahadghao S, Bergenbrant S, Anton D, et al. Anti-idiotypic T cell response in multiple myeloma using dendritic cells as antigen presenting cells [abstract]. Blood 1997; 90 Suppl. 1: 359a
190. 190. Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994; 84: 3017-25
191. 191. Ellis JH, Barber KA, Tull A, et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995; 155: 925-37
192. 192. Demartis A, Bernassola F, Savino R, et al. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996; 56: 4213-18
193. 193. Huang YW, Richardson RA, Vitetta ES. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res 1995; 55: 610-6
194. 194. Hoover RG, Lary C, Page R, et al. Autoregulatory circuits in myeloma. 1 Clin Invest 1995; 95: 241-7
195. 195. Vooijs WC, Schuurman HJ, Bast EJ, et al. Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995; 85: 2282-4
196. 196. Suzuki H, Yasukawa K. Saito T, et al. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992; 22: 1989-93
197. 197. Kreitman RJ, Seigall CB, FitzGerald DJ, et al. Interleukin-6 fused to a mutant form of pseudimonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 1992; 79: 1775-80
198. 198. Ozaki S, Kosaka M, Wakatsuki S, et al. Immunotherpay of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM 1.24. Blood 1997; 90: 3179-86
199. 199. Tsunenari T, Koishihara Y, Nakamura A, et al. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 1997; 90: 2437-44
200. 200. Stewart AK, Trudell S, Buckstein R, et al. Plasma cell vaccination production: negative selection, adenoviral infection and in vivo expression of vector derived interleukin-2 (IL-2) [abstract]. Blood 1997; 90 Suppl. 1: 358a
201. 201. Stewart AK, Hawley TS, Li ZH, et al. Immunogene therapy with interleukin 12 (IL-12), B7-I and Flt3 ligand (Flt3L) in a marine myeloma model: IL-12 and B7-1 expressing cells confer protective immunity [abstract]. Blood 1997; 90 Suppl. 1: 358a-9a